CA3198014A1 - Pharmaceutical composition for oral administration of edaravone and method of administering same - Google Patents

Pharmaceutical composition for oral administration of edaravone and method of administering same

Info

Publication number
CA3198014A1
CA3198014A1 CA3198014A CA3198014A CA3198014A1 CA 3198014 A1 CA3198014 A1 CA 3198014A1 CA 3198014 A CA3198014 A CA 3198014A CA 3198014 A CA3198014 A CA 3198014A CA 3198014 A1 CA3198014 A1 CA 3198014A1
Authority
CA
Canada
Prior art keywords
administration
edaravone
pharmaceutical composition
meal
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3198014A
Other languages
English (en)
French (fr)
Inventor
Hidetoshi Shimizu
Yoshinobu Nakamaru
Yukiko Nishimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81602356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3198014(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CA3198014A1 publication Critical patent/CA3198014A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3198014A 2020-11-12 2021-11-12 Pharmaceutical composition for oral administration of edaravone and method of administering same Pending CA3198014A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020188514 2020-11-12
JP2020-188514 2020-11-12
PCT/JP2021/041673 WO2022102737A1 (ja) 2020-11-12 2021-11-12 エダラボン経口投与用医薬組成物およびその投与方法

Publications (1)

Publication Number Publication Date
CA3198014A1 true CA3198014A1 (en) 2022-05-19

Family

ID=81602356

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3198014A Pending CA3198014A1 (en) 2020-11-12 2021-11-12 Pharmaceutical composition for oral administration of edaravone and method of administering same

Country Status (11)

Country Link
US (2) US11911366B2 (cg-RX-API-DMAC7.html)
EP (1) EP4245303A4 (cg-RX-API-DMAC7.html)
JP (2) JPWO2022102737A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230098267A (cg-RX-API-DMAC7.html)
CN (1) CN116761601A (cg-RX-API-DMAC7.html)
AR (1) AR124062A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021380319B2 (cg-RX-API-DMAC7.html)
CA (1) CA3198014A1 (cg-RX-API-DMAC7.html)
IL (1) IL302533A (cg-RX-API-DMAC7.html)
TW (1) TW202228678A (cg-RX-API-DMAC7.html)
WO (1) WO2022102737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024036261A2 (en) * 2022-08-10 2024-02-15 Kpr U.S., Llc Occlusion detection system and method for a flow control apparatus
EP4559463A1 (en) * 2023-11-23 2025-05-28 Ferrer Internacional, S.A. Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263917A (ja) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk 脳機能正常化剤
JPH0531523A (ja) 1991-07-26 1993-02-09 Aichi Steel Works Ltd ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
CN109125261B (zh) * 2016-03-16 2021-11-30 苏州澳宗生物科技有限公司 依达拉奉剂型
EP3785703A1 (en) * 2017-01-17 2021-03-03 Treeway TW001 B.V. Treatment comprising oral or gastric administration of edaravone
CN110381923A (zh) * 2017-01-17 2019-10-25 萃微Tw001公司 包括肠内施用依达拉奉的医学治疗
BR112021008197A2 (pt) 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral
JP7012792B2 (ja) 2020-08-06 2022-01-28 株式会社 ディー・エヌ・エー 動画を配信するためのシステム、方法、及びプログラム
US12194025B2 (en) 2020-11-12 2025-01-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition for oral administration of edaravone and method of administering same

Also Published As

Publication number Publication date
US12478611B2 (en) 2025-11-25
TW202228678A (zh) 2022-08-01
US20220142982A1 (en) 2022-05-12
JPWO2022102737A1 (cg-RX-API-DMAC7.html) 2022-05-19
AU2021380319B2 (en) 2025-03-20
IL302533A (en) 2023-07-01
US11911366B2 (en) 2024-02-27
CN116761601A (zh) 2023-09-15
AU2025203773A1 (en) 2025-06-12
WO2022102737A1 (ja) 2022-05-19
KR20230098267A (ko) 2023-07-03
US20240173297A1 (en) 2024-05-30
AR124062A1 (es) 2023-02-08
EP4245303A4 (en) 2024-10-09
EP4245303A1 (en) 2023-09-20
JP2025061070A (ja) 2025-04-10
AU2021380319A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
AU2025203773A1 (en) Pharmaceutical composition for oral administration of edaravone and method of administering same
ES2774755T3 (es) Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas
US20160166543A1 (en) Stable combination oral liquid formulation of melatonin and an antihistaminic agent
US12310946B2 (en) Pharmaceutical composition for oral administration of edaravone and method of administering same
EP2754440B1 (en) Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis
US9132134B2 (en) Methods for treating GI tract disorders
US20150320712A1 (en) Nutritional Composition for Gastrostomy-Tube Patients
CN103989677A (zh) 去亚甲基小檗碱在制备降血糖药物中的应用
Nisim et al. Enteral nutrition support
CN103919775A (zh) 9-去甲基小檗碱在制备降血糖药物中的应用
CN109922801A (zh) 甲硝唑和巴氯芬的混悬剂和稀释剂
JP6420797B2 (ja) 活動意欲向上剤
TWI236907B (en) An agent for improving hypoalbuminaemia
BR112017027636B1 (pt) Composições nutricionais líquidas ou semilíquidas e composições nutricionais
EP4559463A1 (en) Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders
US12558347B2 (en) Cevimeline liquid formulations
JP6603450B2 (ja) 高脂血症および/または脂肪肝の改善剤
JP2010265186A (ja) 貧血予防用組成物
CN109223747A (zh) 五加酸在制备抗抑郁症药物中的应用

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241002

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260512